Gilead Sciences, Inc. (GILD)
| Previous close | 67.72 |
| Open | 67.71 |
| Bid | 67.79 x 300 |
| Ask | 67.92 x 300 |
| Day's range | 67.38 - 68.04 |
| 52-week range | 64.33 - 87.87 |
| Volume | |
| Avg. volume | 6,954,506 |
| Market cap | 84.543B |
| Beta (5Y monthly) | 0.23 |
| PE ratio (TTM) | 188.50 |
| EPS (TTM) | 0.36 |
| Earnings date | 08 Aug 2024 |
| Forward dividend & yield | 3.08 (4.55%) |
| Ex-dividend date | 14 June 2024 |
| 1y target est | 74.61 |
Business WireInvestigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
FOSTER CITY, Calif., May 18, 2024--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements in markers of cholestasis and reduced inflammation. Additional findings demonstrate that seladelpar can help reduce pruritus (itch) in people living with primary biliary cholangitis (PBC). There are cu
Business WireKite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
SANTA MONICA, Calif., May 14, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced 12 abstracts from its industry-leading Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upcoming 2024 European Hematology Association (EHA) Annual Congress, June 13-16, Madrid, Spain.
Yahoo FinanceOne stock is dragging down the S&P 500's earnings growth
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
